Pediatrix Medical Group Reiterates 2026 Adjusted EBITDA Outlook
Pediatrix Medical Group (MD) reiterated its 2026 adjusted EBITDA guidance of $280 million to $300 million, the company said Wednesday. The statement was issued in response to recent reports of "shifting utilization and reimbursement trends," with Pediatrix Medical Group saying it has not seen unfavorable payor mix shifts or any material changes in other revenue-related trends.
Pediatrix Medical Group (MD) reiterated its 2026 adjusted EBITDA guidance of $280 million to $300 million, the company said Wednesday.
The statement was issued in response to recent reports of "shifting utilization and reimbursement trends," with Pediatrix Medical Group saying it has not seen unfavorable payor mix shifts or any material changes in other revenue-related trends.